Suboptimal Vitamin K Status Despite Supplementation in Children and Young Adults with Cystic Fibrosis
Overview
Affiliations
Background: For children and adolescents with cystic fibrosis (CF) and pancreatic insufficiency, the efficacy of routine vitamin K supplementation to normalize vitamin K status remains unclear.
Objective: This study examined and determined predictors of vitamin K status in subjects aged 8-25 y with CF and pancreatic insufficiency taking various vitamin K supplements.
Design: In 97 subjects, serum 25-hydroxyvitamin D [25(OH)D], dietary intake, vitamin K supplement intake, and vitamin K statusmdashdetermined on the basis of the percentage of serum undercarboxylated osteocalcin (%ucOC; sufficient: lt 20%) and plasma proteins induced by vitamin K absence-factor II (PIVKA-II; n = 60; sufficient: le 2 microg/L)mdashwere assessed. The vitamin K supplementation groups were as follows: lt 150 microg/d (low; multivitamins or no supplement), 150-999 microg/d (middle; CF-specific vitamins), and ge 1000 microg/d (high; mephyton). %ucOC values were compared with 140 healthy subjects aged 6-21 y.
Results: In subjects with CF, the median (range) %ucOC was 35% (3%, 76%) and the median (range) for PIVKA-II was 2 (0, 42) micro g/L. Subjects with CF had a higher %ucOC with low [45% (10%, 76%)] and medium [41% (3%, 66%)] supplement intakes but not with a high supplement intake [16% (4%, 72%)] compared with healthy subjects [23% (0%, 43%); both P lt 0.05]. Supplementation group for males and females and 25(OH)D and age for males were significant predictors of vitamin K status.
Conclusions: Vitamin K status was often suboptimal despite routine supplementation. Only subjects taking high-dose vitamin K achieved a status similar to healthy subjects, and only the vitamin K supplementation dose predicted vitamin K status for males and females. These data suggest that higher doses of vitamin K are required.
Krzyzanowska-Jankowska P, Nowak J, Karazniewicz-Lada M, Jamka M, Klapkova E, Kurek S Nutrients. 2024; 16(9).
PMID: 38732584 PMC: 11085146. DOI: 10.3390/nu16091337.
Soleimanzadeh M, Talebi S, Jaafari M, Sayedi S, Emadzadeh M, Kianifar H Trials. 2024; 25(1):60.
PMID: 38229125 PMC: 10792794. DOI: 10.1186/s13063-023-07896-8.
Macronutrient and Micronutrient Intake in Children with Lung Disease.
Knebusch N, Mansour M, Vazquez S, Coss-Bu J Nutrients. 2023; 15(19).
PMID: 37836425 PMC: 10574027. DOI: 10.3390/nu15194142.
Role of innate immunity and systemic inflammation in cystic fibrosis disease progression.
Purushothaman A, Nelson E Heliyon. 2023; 9(7):e17553.
PMID: 37449112 PMC: 10336457. DOI: 10.1016/j.heliyon.2023.e17553.
Nutritional Care in Children with Cystic Fibrosis.
Mariotti Zani E, Grandinetti R, Cunico D, Torelli L, Fainardi V, Pisi G Nutrients. 2023; 15(3).
PMID: 36771186 PMC: 9921127. DOI: 10.3390/nu15030479.